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P ¼ .22). Median lymphocyte counts did not increase
between 3 and 12 months in the PD group as in the U+UD
group, but the proportion of CD3+ cells within lymphocytes
increased in both groups. PD T cell repertoires were less
clonal than U+UD samples at 3 months (1-normalized
entropy: 0.14 vs. 0.25, P ¼ .09) and 12 months (1-normalized
entropy: 0.11 vs. 0.23, P ¼ .95), with more even frequency
distribution of TCRs. PD T cell repertoire was more dynamic
than the U+UD controls with a signiﬁcantly decreased T cell
clonal persistence between 3 and 12 months (TCR sequence
overlap: 8.73% vs. 38.84%, P ¼ .027).
Conclusions: Ex vivo dmPGE2 modulation with dmPGE2
dominance results in delayed Tcell and lymphocyte recovery,
but less clonality despite a T cell repertoire restricted by low
CD3+ counts. The reduced oligoclonality and rapid T cell
turnover may indicate enhanced thymopoiesis. Correlation
with TRECs and clinical infectious outcomes is ongoing.
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Amaya Zabalza 1,2, Miriam Ciaurriz 2, Lorea Beloki 2,
Natalia Ramirez 2, Ana Gorosquieta 1,
Mercedes Rodriguez Calvillo 1, Eva Bandres 1, Cristina Mansilla 2,
Eduardo Olavarria 1,2. 1 Complejo Hospitalario de Navarra;
2 Biomedical Research Center of Navarra
CMV reactivation after allo-SCT is usually monitored by
CMV-PCR. We present the results of a pilot study looking at
the additional use of Multimers for monitoring CMV-speciﬁc
CD8+ T-cells at different intervals after allo-SCT.
10 patients (4 males) that underwent allo-SCT from HLA-
identical siblings (n¼4) or HLA-matched unrelated (n¼6)
donors between May 2010 and May 2012 were enrolled. The
diagnosis was acute leukemia (n¼6), lymphoproliferative
disorders (n¼2) and myelodysplastic syndromes (n¼2). All
patients and 8 donors were CMV seropositive. All patients
were positive for the HLA-A*0201 allele. Pentamers (Proim-
mune, UK) and Streptamers (Gottingen GmbH, Germany)
were directed against the epitope NLVPMVATV of the
pp65495-503 protein of CMV in the context of HLA-A*0201.
Samples were obtained from engraftment at 30-day intervals
until day +180 and 2-monthly thereafter.
The median follow-up was 12.6 (4-21) months after SCT.
Engraftment occurred in all patients at a median of 21.2 (15-
27) days. Acute GVHD was diagnosed in 4 patients at
a median of 63.3 (25-92) days. One patient developed acute
GVHD following infusion of donor lymphocytes for the
treatment of mixed chimerism on day +323.
Three patterns were observed. In 2 patients no CMV-
speciﬁc CD8+ T-cells could be detected after SCT despite
several episodes of CMV-PCR reactivation requiring pro-
longed antiviral treatment. In 5 patients CMV-PCR reac-
tivation triggered a rapid increase of CMV-speciﬁc CD8+
T-cells (median 112.2 x 105/L, range 1.3-279.7 x 105/L).
However, the CMV-PCR became immediately negative and
antiviral treatment was stopped in all reactivations within 2
weeks. Subsequent CMV-PCR reactivations also lasted under
2 weeks in this group. Finally, 3 patients showed an early
immune reconstitution with CMV-speciﬁc CD8+ T-cells
detected (median 1.3 x 105/L, range 0.3-2.3 x 105/L) at
a median of 21 (17-33) days post-SCT. No CMV-PCR reac-
tivation was observed in this group.
We conclude that monitoring CMV-speciﬁc T-cell immu-
nity after allo-SCT in combination with CMV-PCR may be
able to distinguish patients at higher risk of CMV reactivationand in need of prolonged antiviral therapy. Patients with
CMV-speciﬁc CD8+ T-cells detectable at the time of CMV-PCR
reactivation may only need a short course of antiviral
therapy, while those with early and persistent CMV-speciﬁc
CD8+ T-cells may be at a very low risk of developing CMV
disease in the long-term.189
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Recent studies show that accelerated gd T cell reconsti-
tution after hematopoietic stem cell transplantation (HSCT)
is associated with improved overall survival (OS) though the
mechanisms have not been elucidated. We evaluated 102
consecutive pediatric patients with acute leukemia under-
going HSCT at St. Jude Children's Research Hospital from
1996-2011. Themedian age of the patients was 10.5 5.9 yrs.
(range, 0.6-25.2) and median follow up was 2.71.8 yrs.
(range 0.2-6.0). There were 57% males, 43% females and 59%
with ALL and 41% with AML. There were 14 patients with
elevated gd T cells (1.75x105 cells/ml) and 88 with low/
normal gd T cells (<1.75x105 cells/ml). There were no
signiﬁcant differences between the two groups with respect
to age, sex, disease or donor source, p¼0.7, 0.5, 1 and 0.07
respectively. Fours years after HSCT, Overall Survival (OS)
was signiﬁcantly higher for patients in the elevated group
compared to the patients in the low/normal group, 93% and
60%, respectively, p¼0.0173. Survival without relapse or graft
failure, Event Free Survival (EFS), was signiﬁcantly higher in
the elevated group compared to the low/normal group, 85.7%
and 58.0%, respectively. Since T cell reconstitution following
HSCT is age dependent, we determined if gd T cell recovery
correlated with age and/or CD3+ cells. Multivariate analysis
showed no correlation between the number of CD3+ and gd T
cells. In fact, 13 of 14 patients that recovered with increased
number of gd T cells had normal or low numbers of CD3+
cells. Thus, gd T cell recovery is not a simple correlate of T cell
reconstitution. Because gd T cells play a central role in
maintaining intestinal epithelium integrity, we evaluated the
incidence of gut GVHD. We found a signiﬁcant lower rate of
gut GVHD in the elevated group compared to the low/normal
group, 0% and 17% respectively. Furthermore, the number of
gd T cells in patients with cGVHD (2.3 x105 cells/ml) was
signiﬁcantly lower compared to patients without cGVHD (6.2
x105 cells/ml), p¼0.01. This suggests that gd T cell may
protect against gut and cGVHD. Since accumulating evidence
suggests that gd T cells contribute to both innate and adap-
tive immune responses during infections, we evaluated the
rate and types of infection between the two groups. We
found a signiﬁcant lower incidence of infections reported
in the elevated group compared to the low/normal group,
21% and 54% respectively p¼0.02. Furthermore, the elevated
group had only viral infections while the low/normal group
had viral, bacterial and fungal infections. In summary, this is
the ﬁrst reported study of gd T cell recovery after HSCT in
pediatric patients and adds new insights into the role gd T
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Background: CBT recipients may respond to post-transplant
vaccines differently than other transplant groups due to the
lack of transfer of donor immunity.
Methods: We analyzed vaccine responses in 48 CBT recipi-
ents transplanted at our center from 2005-2010 for the
treatment of hematologic malignancies with myeloablative
or non-myeloablative conditioning. GHVD ppx included
a calcineurin-inhibitor and MMF. All patients received
double unit CB grafts and no pt received ATG. Vaccination
criteria included CD4+ cell count > 200 cells/ul and IgG level
> 500 mg/dl at > 6 weeks following the last IVIG dose.
Results: Forty-eight of 69 (70%) eligible pts alive & disease-
free @ 12 months post-HCT were vaccinated. Vaccinated
patients engrafted with 6/6 (n ¼ 2), 5/6 (n ¼ 26), or 4/6 (n ¼
20) HLA-matched units. Twelve pts received rituximab
(median 4 doses) as planned peri-transplant therapy for B-
cell malignancies (n ¼ 6), EBV viremia/ lymphoma (n ¼ 3),
autoimmune hemolysis (n ¼ 1), pure red cell aplasia (n ¼ 1),
or recurrent disease (n¼1). Prior to immunization, 13
patients had no acute or chronic GVHDwhereas 35 had prior
grade II-IV acute and/or chronic GHVD. Overall, the median
time to vaccination was 16.9 months post-CBT; 18.9 months
in pts who received rituximab; 15.23 months in those who
did not (P¼ .056). Pre-vaccination titers obtained at amedian
of 1 yr demonstrated that> 85% of patients lacked protection
against pneumococcus, H. ﬂu, and pertussis and > 50%
lacked immunity against tetanus, measles, & mumps. Sero-
conversion or > 3- fold rise in titer was observed in > 60% of
patients in response to tetanus, diphtheria, H. ﬂu, polio and
pneumococcal (PCV7 or PCV13) vaccines. Following 3 doses
of rHBV vaccine, 52% pt seroconverted. Only 2/35 recipients
of a single Tdap developed protective pertussis titers; 0/8 pts
responded to a single protein-conjugated meninogoccal
vaccine. To date, 20 pts including 9 adults have received an
MMR at a median of 2.3 years post-CBT. 8 pts received the
live attenuated varicella vaccine. To date, seroconversion
following measles, mumps, & rubella vaccine occurred in
56%, 41% & 93% of pts, respectively and 5 evaluable pts
seroconverted after 1 (n¼3) or 2 doses of Varivax (n ¼ 2).
Survival in vaccinated patients is 100%. No serious reactions
to any vaccine occurred.
Conclusion: CBT recipients, including adults & those with
prior GVHD or rituximab therapy, are capable of responding
to tetanus, diphtheria, H. ﬂu, polio & PCV7 or PCV13 similar
to other transplant groups. The sub-optimal response to
pathogens associated with outbreaks in the community
(Hepatitis B, Pertussis, meningococcus, measles, mumps,
varicella) highlight the need to obtain pre- & post-vaccine
titers to document response, and the need to deﬁne the
optimal vaccination regimen in this population.191
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The rate of immune reconstitution (IR) is directly correlated
with thenumberofhematopoietic stemcells (HSC) infusedand
is particularly delayed in patients undergoing cord blood
transplantation (CBT) secondary to the limited numbers of
HSC. Thus, methods to increase the number of cord blood (CB)
progenitors have the potential to accelerate IR after CBT.
Natural killer (NK) cells play a crucial role in early IR after HCT
because they are the ﬁrst lymphocyte subset to recover after
transplant. CB NK cells have been reported to have incomplete
maturation and require activation for effective function. Here,
we report a clinically relevant method for ex vivo expansion of
NKcells isolated fromCBwithout theuseof a stromal layer.Our
group has demonstrated that CB NK cells cultured in the
presence of IL-2 and IL-15 results in amulti-log increase in the
number of precursors that have a signiﬁcant increase in cyto-
toxicity against several target cancer cell lines. After 21 days in
culture, there is a 1.848 0.341 log fold increase in the number
of CD3-CD56+ NK cells (range, 0.420 to 3.108) (P < .001, N¼9).
After culture, we also found a signiﬁcant 2.612 0.310 log fold
increase (range, 0.979 to 3.622) (P< .001, N¼9) in the number
of CD3+CD56+ NKT cells. Evaluation of cytotoxicity against
K562cells, a chronicmyelogenous leukemia, showedtherewas
also a signiﬁcant increase in cytolytic function at days 14 (31.52
 8.317% target cell lysis, P< .01, N¼8) and 21 (44.22 9.866%
target cell lysis, P< .01, N¼8) in culturewhen compared to day
of isolation; similar results were seen using Jurkat cells, an
acute T-cell lymphoblastic leukemia (T-ALL). Evaluation of NK
cell resistant cells lines was also tested. While we found an
increase in cytotoxicity toward the myeloid lymphoid
leukemia cell line (MLL), MV411, after culture, the RS411 (MLL/
ALL) and HDLM2 (Hodgkin's lymphoma) cell lines remained
resistant to cytolytic killing (N¼3). Currently, we are investi-
gating the NK cell population(s) responsible for the cytotoxic
killing and the corresponding killer cell Ig-like receptor (KIR)
ligand/adhesion molecule(s) that may be responsible for
function. We hypothesize that using methods to increase the
number of CB NK cells have the potential to prevent early
relapse, infections and graft versus host disease, as well as
facilitate engraftment when administered following CBT.
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Tissue engineering approaches based on implantation of
biomimetic three-dimensional (3D) tissue constructs have
been used for more than a decade for in vivo regeneration of
